tiprankstipranks
Trending News
More News >
Oxford BioMedica plc (GB:OXB)
LSE:OXB

Oxford BioMedica (OXB) AI Stock Analysis

Compare
65 Followers

Top Page

GB

Oxford BioMedica

(LSE:OXB)

Rating:56Neutral
Price Target:
345.00p
▲(2.22%Upside)
Oxford BioMedica's stock score reflects strong earnings call sentiment and positive technical indicators, tempered by financial instability and challenging valuation. Corporate events offer additional support, but profitability concerns remain significant risks.
Positive Factors
Earnings Potential
OXB is targeting an operating EBITDA profit for 2025, supported by a healthy contracted order book.
Revenue Growth
OXB delivered revenues of £128.8m, representing 44% growth YoY.
Negative Factors
Macroeconomic Concerns
There is a level of caution on the outlook due to uncertain macroeconomic headwinds and a tight funding environment.

Oxford BioMedica (OXB) vs. iShares MSCI United Kingdom ETF (EWC)

Oxford BioMedica Business Overview & Revenue Model

Company DescriptionOxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
How the Company Makes MoneyOxford BioMedica generates revenue through multiple streams, primarily centered around its expertise in lentiviral vector technology. The company earns money by collaborating with pharmaceutical and biotechnology companies, providing them with development and manufacturing services for gene and cell therapy products. This includes licensing its proprietary technologies and platforms, as well as entering into strategic partnerships and agreements that often include upfront payments, milestone payments, and royalties on product sales. Additionally, OXB may invest in proprietary drug development, aiming to generate future revenue through the commercialization of its own therapeutic products. Significant partnerships with major industry players such as Novartis contribute to its earnings by leveraging OXB's unique capabilities in vector production and development.

Oxford BioMedica Earnings Call Summary

Earnings Call Date:Sep 23, 2024
(Q4-2024)
|
% Change Since: 31.84%|
Next Earnings Date:Apr 09, 2025
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with significant revenue growth, increased client orders, operational efficiency improvements, and strategic expansions. However, challenges such as the operating EBITDA loss and negative working capital movement were noted.
Q4-2024 Updates
Positive Updates
Impressive Organic Revenue Growth
The company achieved an organic revenue growth of 81% and total revenues increased by 44% to GBP128.8 million in 2024.
Record Client Orders
The contracted value of client orders reached GBP186 million in 2024, a 35% increase from the previous year.
Operational Efficiency
Operating EBITDA loss narrowed significantly from GBP52.8 million in 2023 to GBP15.3 million in 2024, with a GBP5 million operating EBITDA profit in the second half of 2024.
Strong Commercial Momentum
The company reported significant growth in its pipeline, with a risk-adjusted pipeline growth of 61% from 2022 to 2024.
Successful FDA Inspection
The FDA inspection of the Oxford manufacturing site in July 2024 resulted in zero written observations, highlighting the quality management system.
Strategic Expansion and Rebranding
Completed acquisition of OXB in France, expanding operational footprint, and rebranded as OXB establishing a unified brand across geographies.
Negative Updates
Operating EBITDA Loss
Despite improvements, the company reported an operating EBITDA loss of GBP15.3 million for 2024.
Negative Working Capital Movement
The net cash outflow during 2024 was GBP42.1 million, largely driven by a negative working capital movement of GBP35.4 million.
Company Guidance
In the 2024 analyst briefing, OXB reported strong financial performance with an impressive organic revenue growth of 81%, resulting in total revenues of GBP128.8 million, a 44% increase from the previous year. Their pipeline expanded by 30% to $570 million, and customer orders grew by 35% to GBP186 million. The company achieved an operating EBITDA profit of GBP5 million in the second half of the year, narrowing their annual operating EBITDA loss to GBP15.3 million, a significant improvement from 2023's GBP52.8 million loss. For 2025, OXB expects revenues between GBP160 million and GBP170 million, with over 80% of this already covered by existing orders. The company plans to achieve a low single-digit million operating EBITDA profit, with a focus on continued margin expansion driven by operational efficiencies and strong commercial momentum.

Oxford BioMedica Financial Statement Overview

Summary
Oxford BioMedica exhibits strong revenue growth but struggles with profitability and cash flow. The negative net and gross profit margins, combined with high leverage and liquidity issues, indicate significant financial challenges.
Income Statement
45
Neutral
Oxford BioMedica's income statement reveals significant volatility in revenue and net income over the years. The most recent year shows a positive revenue growth of 43.84% from the previous year, but the company continues to face profitability challenges with a negative net profit margin of -33.53% and a negative gross profit margin of 40.65%. EBIT and EBITDA margins are also negative, indicating ongoing operational challenges.
Balance Sheet
50
Neutral
The balance sheet analysis shows a high level of debt relative to equity, with a debt-to-equity ratio of 1.91, posing a risk to financial stability. However, the equity ratio stands at 24.62%, reflecting some level of financial cushioning. Return on equity is negative due to sustained losses, highlighting profitability concerns.
Cash Flow
40
Negative
Cash flow analysis indicates negative free cash flow growth and operating cash flow, pointing to liquidity issues. The free cash flow to net income ratio is 1.35, suggesting that the company is not generating sufficient free cash flow to cover its net losses, which could put pressure on future operations.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
128.80M89.54M139.99M142.80M87.73M
Gross Profit
53.02M39.73M69.18M82.64M46.07M
EBIT
-39.38M-184.17M-51.56M20.77M-4.83M
EBITDA
-14.33M-148.62M-10.86M33.22M3.92M
Net Income Common Stockholders
-43.19M-157.49M-45.16M19.01M-6.25M
Balance SheetCash, Cash Equivalents and Short-Term Investments
60.65M103.72M141.31M109.02M46.98M
Total Assets
231.64M252.34M460.18M237.23M183.93M
Total Debt
108.76M111.46M114.28M9.34M13.85M
Net Debt
48.11M7.74M-27.00M-99.60M-32.90M
Total Liabilities
171.16M174.51M223.99M49.89M71.18M
Stockholders Equity
57.05M74.01M204.65M187.34M112.75M
Cash FlowFree Cash Flow
-58.12M-38.35M-28.91M15.99M-10.24M
Operating Cash Flow
-50.63M-28.52M-12.62M25.45M3.12M
Investing Cash Flow
5.63M2.81M-56.46M-9.46M-10.80M
Financing Cash Flow
2.91M-12.70M98.62M46.21M38.19M

Oxford BioMedica Technical Analysis

Technical Analysis Sentiment
Positive
Last Price337.50
Price Trends
50DMA
299.30
Positive
100DMA
329.00
Positive
200DMA
361.82
Negative
Market Momentum
MACD
11.57
Negative
RSI
61.98
Neutral
STOCH
78.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OXB, the sentiment is Positive. The current price of 337.5 is above the 20-day moving average (MA) of 315.68, above the 50-day MA of 299.30, and below the 200-day MA of 361.82, indicating a neutral trend. The MACD of 11.57 indicates Negative momentum. The RSI at 61.98 is Neutral, neither overbought nor oversold. The STOCH value of 78.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:OXB.

Oxford BioMedica Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
GBOXB
56
Neutral
$364.43M-66.23%43.84%74.88%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
£125.57M-73.02%
65
Neutral
£333.86M8.5411.74%38.80%
46
Neutral
£108.86M167.16%-100.00%-23.91%
GB4BB
£171.74M-95.28%
GBONT
61
Neutral
£1.15B-23.77%7.97%12.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:OXB
Oxford BioMedica
337.50
12.00
3.69%
GB:AVCT
Avacta Group plc
33.00
-7.75
-19.02%
GB:PRTC
PureTech Health
139.80
-85.20
-37.87%
GB:SCLP
Scancell Holdings
10.50
1.10
11.70%
GB:4BB
4basebio UK Societas
1,110.00
-485.00
-30.41%
GB:ONT
Oxford Nanopore Technologies PLC
123.60
20.70
20.12%

Oxford BioMedica Corporate Events

Delistings and Listing ChangesPrivate Placements and Financing
Oxford Biomedica Seeks Block Listing on London Stock Exchange
Positive
Jun 5, 2025

Oxford Biomedica has applied for a block listing of 250,000 ordinary shares on the London Stock Exchange, as part of its Long Term Incentive Plan. This move is expected to enhance the company’s market presence and provide additional capital for its operations, reinforcing its position as a leader in the cell and gene therapy industry.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £5.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Business Operations and Strategy
Oxford Biomedica Launches Innovation and Technology Excellence Board
Positive
Jun 3, 2025

Oxford Biomedica has launched its Innovation and Technology Excellence Board (ITEB) to enhance its position as a leader in cell and gene therapy. The board, comprising experts in the field, will guide the company on technology priorities and innovation opportunities, aiming to improve scientific capabilities and maintain OXB’s market-leading status. This initiative is expected to strengthen OXB’s value proposition to clients and support the development of transformative therapies.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Regulatory Filings and Compliance
Oxford Biomedica Announces Total Voting Rights Update
Neutral
Jun 2, 2025

Oxford Biomedica PLC announced that its issued share capital as of May 31, 2025, consists of 106,093,858 ordinary shares, with no shares held in treasury. This figure represents the total number of voting rights in the company, which shareholders can use to determine their notification requirements under FCA rules.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Oxford Biomedica Awards Share Options to Leadership
Positive
May 16, 2025

Oxford Biomedica has announced the grant of nil-cost share options under its 2024 Long Term Incentive Plan and Deferred Bonus Plan. These grants, aimed at aligning with the company’s growth strategy, focus on key metrics such as EBITDA margin and revenue growth, which are crucial for stakeholders and reflect the company’s commitment to incentivizing its leadership team.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Regulatory Filings and Compliance
Oxford Biomedica Announces Share Transaction by Associated Person
Neutral
Apr 30, 2025

Oxford Biomedica announced that Pippa Radcliffe, closely associated with the company’s Chief Innovation Officer, Dr. Kyriacos Mitrophanous, exercised 1,209 options and sold 1,209 shares at £2.9785 per share. This transaction, compliant with EU Market Abuse Regulation, reflects internal financial activities and may impact stakeholders’ perceptions of the company’s governance and financial health.

Business Operations and StrategyRegulatory Filings and Compliance
Oxford BioMedica Sees Change in Major Shareholder Voting Rights
Neutral
Apr 29, 2025

Oxford BioMedica PLC has announced a change in its major shareholders, with Briarwood Chase Management LLC acquiring a significant increase in voting rights, now holding 12.019% of the total. This acquisition indicates a strengthened position for Briarwood Chase Management in the company, potentially influencing future strategic decisions and impacting stakeholder interests.

Shareholder Meetings
Oxford Biomedica Announces 2025 Annual General Meeting Details
Neutral
Apr 28, 2025

Oxford Biomedica PLC has announced the notice of its Annual General Meeting (AGM) for 2025, which will be held on 11 June at its Oxford offices. The company has made the AGM notice and its 2024 Annual Report available to shareholders and submitted them to the Financial Conduct Authority for public access. This announcement is part of OXB’s ongoing commitment to transparency and stakeholder engagement, reflecting its strategic focus on maintaining strong governance and communication with its investors.

Business Operations and Strategy
Oxford BioMedica Sees Stake Increase by Briarwood Chase Management
Neutral
Apr 23, 2025

Oxford BioMedica PLC has announced a change in its voting rights, with Briarwood Chase Management LLC increasing its stake to 11.03% from a previous 10.54%. This acquisition of voting rights signifies a significant shift in shareholder influence, potentially impacting the company’s strategic decisions and stakeholder interests.

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Oxford BioMedica Reports Robust 2024 Financial Performance and Strategic Expansion
Positive
Apr 9, 2025

Oxford BioMedica reported strong financial results for 2024, with a 44% increase in revenue to £128.8 million and an 81% organic growth rate. The company’s strategic expansion, including the acquisition of ABL Europe, has bolstered its global operations, particularly in viral vector platforms. The company achieved an operating EBITDA profit in the second half of 2024 and anticipates profitability for FY 2025. The growth reflects increased demand across all vector segments, with a notable rise in contracted client orders, signaling robust commercial momentum and positioning OXB for continued success in the cell and gene therapy market.

Other
Briarwood Chase Increases Stake in Oxford BioMedica
Neutral
Apr 4, 2025

Oxford BioMedica PLC has announced a significant change in its shareholder structure, as Briarwood Chase Management LLC has increased its voting rights in the company to 10.54%, up from a previous 5.12%. This acquisition of voting rights highlights Briarwood Chase’s growing influence within the company, potentially impacting future strategic decisions and stakeholder interests.

Executive/Board ChangesBusiness Operations and Strategy
Oxford Biomedica’s Colin Bond Joins Faron Pharmaceuticals as Non-Executive Director
Neutral
Mar 27, 2025

Oxford Biomedica PLC announced the appointment of Colin Bond, a Non-Executive Director, to a similar role at Faron Pharmaceuticals Ltd, an AIM-listed company. This move reflects OXB’s strategic positioning within the cell and gene therapy industry, potentially strengthening its network and influence through leadership roles in related companies.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.